Examkin

Question

Difficulty: Very hardDepressive Disorders

A 42-year-old woman presents to the oncology clinic for a routine follow-up. She was diagnosed with estrogen receptor-positive breast cancer 8 months ago, underwent a lumpectomy and radiation therapy, and is currently taking tamoxifen. When asked about her general well-being, she reports an 8-week history of profound fatigue, sleeping up to 14 hours a day, increased appetite with a 4-kg (8.8-lb) weight gain, and a heavy, "leaden" feeling in her arms and legs that makes it difficult to get out of bed. Her functional impairment is significant, and she recently took a leave of absence from her job. A review of her psychiatric history reveals a similar depressive episode at age 22. Further questioning reveals that at age 24, she experienced a 5-day period where she felt "euphoric and invincible," required only 3 hours of sleep per night, and rapidly outlined a 300-page screenplay. This period resolved spontaneously without hospitalization. Last week, her primary care physician diagnosed her with depression and prescribed paroxetine, but the patient discontinued it after 2 days due to mild nausea. She currently takes no medications other than tamoxifen. Vital signs and physical examination are unremarkable. Which of the following is the most appropriate next step in the pharmacological management of this patient's psychiatric symptoms?

  1. Initiate lurasidoneAnswer
  2. B
    Resume paroxetine and add ondansetron
  3. C
    Initiate bupropion
  4. D
    Initiate fluoxetine and olanzapine
  5. E
    Initiate venlafaxine

Answer

Initiate lurasidone
This patient meets the criteria for Bipolar II disorder (current episode depressed with atypical features) based on her history of a major depressive episode and a distinct 5-day period of hypomania (euphoria, decreased need for sleep, increased goal-directed activity lasting ≥\geq 4 days without requiring hospitalization). Standard antidepressant monotherapy is generally contraindicated in bipolar depression due to the risk of precipitating a manic or hypomanic switch. First-line treatments for bipolar depression include lurasidone, quetiapine, cariprazine, and the olanzapine-fluoxetine combination. Furthermore, this patient is taking tamoxifen for breast cancer. Tamoxifen is a prodrug that requires activation by the cytochrome P450 2D6 (CYP2D6) enzyme to its active metabolite, endoxifen. Lurasidone does not significantly inhibit CYP2D6 and is an FDA-approved, effective monotherapy for bipolar depression, making it the safest and most appropriate choice.

Step-by-Step Solution

1
Diagnose the psychiatric condition based on the timeline and clinical features.
The patient has Bipolar II disorder, currently in a major depressive episode with atypical features.
She has a history of a major depressive episode and a distinct 5-day period of elevated mood, decreased need for sleep, and increased goal-directed activity (hypomania requires ≥4 days without hospitalization/psychosis). Her current episode features hypersomnia, hyperphagia, and leaden paralysis (atypical features).
2
Determine the appropriate class of psychiatric medications.
Standard antidepressant monotherapy (SSRIs, SNRIs, bupropion) is contraindicated due to the risk of precipitating a hypomanic/manic switch.
First-line treatments for bipolar depression include lurasidone, quetiapine, cariprazine, and olanzapine-fluoxetine combination.
3
Analyze the pharmacological constraints presented by the patient's medical history.
The patient is taking tamoxifen, a prodrug that requires activation by the CYP2D6 enzyme into its active metabolite, endoxifen.
Strong CYP2D6 inhibitors (such as paroxetine, fluoxetine, and bupropion) must be strictly avoided to prevent breast cancer recurrence.
4
Select the optimal agent that fulfills both psychiatric and pharmacological requirements.
Lurasidone is selected as it treats bipolar depression effectively without significantly inhibiting CYP2D6.
It addresses the mood episode safely without compromising the patient's oncologic treatment.

Key Concept

Management of Bipolar II depression in patients taking tamoxifen requires avoiding antidepressant monotherapy (due to manic switch risk) and avoiding strong CYP2D6 inhibitors (due to negation of tamoxifen efficacy).
Rate this question

Topics

Depressive Disorders

More questions from this topic